GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (FRA:VM4) » Definitions » Other Operating Expense

Vanda Pharmaceuticals (FRA:VM4) Other Operating Expense : €3.4 Mil (TTM As of Mar. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Vanda Pharmaceuticals Other Operating Expense?

Vanda Pharmaceuticals's Other Operating Expense for the three months ended in Mar. 2024 was €1.9 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 was €3.4 Mil.

Vanda Pharmaceuticals's quarterly Other Operating Expense increased from Sep. 2023 (€0.4 Mil) to Dec. 2023 (€0.9 Mil) and increased from Dec. 2023 (€0.9 Mil) to Mar. 2024 (€1.9 Mil).

Vanda Pharmaceuticals's annual Other Operating Expense increased from Dec. 2021 (€1.3 Mil) to Dec. 2022 (€1.4 Mil) and increased from Dec. 2022 (€1.4 Mil) to Dec. 2023 (€1.9 Mil).


Vanda Pharmaceuticals Other Operating Expense Historical Data

The historical data trend for Vanda Pharmaceuticals's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vanda Pharmaceuticals Other Operating Expense Chart

Vanda Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.36 1.22 1.31 1.43 1.92

Vanda Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.35 0.35 0.36 0.87 1.86

Vanda Pharmaceuticals Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vanda Pharmaceuticals Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Vanda Pharmaceuticals's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Vanda Pharmaceuticals (FRA:VM4) Business Description

Traded in Other Exchanges
Address
2200 Pennsylvania Avenue NW, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include VHX-896 and ASO Molecules. The majority of revenue is derived from HETLIOZ product sales.

Vanda Pharmaceuticals (FRA:VM4) Headlines

No Headlines